Aimfinity Investment Corp. I Announces Transition from Nasdaq to OTC Markets and New Monthly Extension for Business Combination
Aimfinity Investment has announced its transition from Nasdaq to OTC Markets, with trading expected to begin on May 5, 2025, under the tickers "AIMAU," "AIMBU," and "AIMAW" for its various securities.
The company's pending business combination with Docter, a Taiwanese health technology company, which received shareholder approval on March 27, 2025, will proceed as planned despite the venue change. Both companies remain committed to securing Nasdaq listing approval for the post-combined entity.
Additionally, I-Fa Chang, the sponsor's manager, has deposited $55,823.80 ($0.05 per Class A ordinary share) into the trust account to extend the business combination deadline from April 28 to May 28, 2025. This marks the fourth of nine possible monthly extensions available under the company's charter, which allows extensions until October 28, 2025.
Aimfinity Investment ha annunciato il passaggio dal Nasdaq ai mercati OTC, con l'inizio delle contrattazioni previsto per il 5 maggio 2025, sotto i ticker "AIMAU", "AIMBU" e "AIMAW" per i suoi diversi titoli.
La combinazione aziendale in sospeso con Docter, una società taiwanese di tecnologia sanitaria, che ha ottenuto l'approvazione degli azionisti il 27 marzo 2025, procederà come previsto nonostante il cambio di mercato. Entrambe le società restano impegnate a ottenere l'approvazione per la quotazione Nasdaq dell'entità combinata.
Inoltre, I-Fa Chang, il manager dello sponsor, ha depositato 55.823,80 dollari (0,05 dollari per azione ordinaria di Classe A) nel conto fiduciario per estendere la scadenza della combinazione aziendale dal 28 aprile al 28 maggio 2025. Questa è la quarta delle nove possibili estensioni mensili previste dallo statuto della società, che consente proroghe fino al 28 ottobre 2025.
Aimfinity Investment ha anunciado su transición de Nasdaq a los mercados OTC, con el inicio de las operaciones previsto para el 5 de mayo de 2025, bajo los símbolos "AIMAU", "AIMBU" y "AIMAW" para sus diferentes valores.
La combinación empresarial pendiente con Docter, una empresa taiwanesa de tecnología sanitaria, que recibió la aprobación de los accionistas el 27 de marzo de 2025, continuará según lo planeado a pesar del cambio de mercado. Ambas compañías mantienen su compromiso de obtener la aprobación para la cotización en Nasdaq de la entidad combinada.
Además, I-Fa Chang, el gerente del patrocinador, ha depositado 55,823.80 dólares (0.05 dólares por acción ordinaria Clase A) en la cuenta fiduciaria para extender el plazo de la combinación empresarial del 28 de abril al 28 de mayo de 2025. Esta es la cuarta de nueve posibles extensiones mensuales permitidas por los estatutos de la compañía, que permiten extensiones hasta el 28 de octubre de 2025.
Aimfinity Investment는 나스닥에서 OTC 마켓으로 전환할 예정이며, 2025년 5월 5일부터 "AIMAU", "AIMBU", "AIMAW"라는 티커로 다양한 증권의 거래가 시작될 예정입니다.
대만 건강 기술 회사인 Docter와의 사업 결합은 2025년 3월 27일 주주 승인 후 예정대로 진행되며, 거래 장소 변경에도 불구하고 양사는 합병 후 나스닥 상장 승인을 받기 위해 계속 노력할 것입니다.
또한, 스폰서 매니저인 I-Fa Chang은 2025년 4월 28일에서 5월 28일로 사업 결합 기한을 연장하기 위해 클래스 A 보통주당 0.05달러, 총 55,823.80달러를 신탁 계좌에 입금했습니다. 이는 회사 정관에 따라 최대 2025년 10월 28일까지 연장이 가능한 총 9회 중 네 번째 월별 연장입니다.
Aimfinity Investment a annoncé sa transition du Nasdaq vers les marchés OTC, avec un début des échanges prévu le 5 mai 2025 sous les tickers "AIMAU", "AIMBU" et "AIMAW" pour ses différents titres.
La fusion d'entreprise en attente avec Docter, une société taïwanaise de technologie de la santé, qui a reçu l'approbation des actionnaires le 27 mars 2025, se poursuivra comme prévu malgré le changement de place de marché. Les deux sociétés restent engagées à obtenir l'approbation de la cotation Nasdaq pour l'entité fusionnée.
De plus, I-Fa Chang, le gestionnaire du sponsor, a déposé 55 823,80 $ (0,05 $ par action ordinaire de classe A) sur le compte fiduciaire pour prolonger la date limite de la fusion d'entreprise du 28 avril au 28 mai 2025. Il s'agit de la quatrième des neuf extensions mensuelles possibles prévues par les statuts de la société, qui autorisent des prolongations jusqu'au 28 octobre 2025.
Aimfinity Investment hat den Wechsel vom Nasdaq zu den OTC-Märkten angekündigt, wobei der Handel ab dem 5. Mai 2025 unter den Tickersymbolen "AIMAU", "AIMBU" und "AIMAW" für verschiedene Wertpapiere beginnen soll.
Die ausstehende Geschäftskombination mit Docter, einem taiwanesischen Gesundheitstechnologieunternehmen, das am 27. März 2025 die Zustimmung der Aktionäre erhalten hat, wird trotz des Marktplatzwechsels planmäßig fortgesetzt. Beide Unternehmen sind weiterhin bestrebt, die Nasdaq-Notierungszulassung für die fusionierte Einheit zu erhalten.
Darüber hinaus hat I-Fa Chang, der Manager des Sponsors, 55.823,80 USD (0,05 USD pro Class-A-Stammaktie) auf das Treuhandkonto eingezahlt, um die Frist für die Geschäftskombination vom 28. April auf den 28. Mai 2025 zu verlängern. Dies ist die vierte von neun möglichen monatlichen Verlängerungen gemäß der Satzung des Unternehmens, die Verlängerungen bis zum 28. Oktober 2025 erlaubt.
- Shareholders approved business combination with Docter on March 27, 2025
- Successfully secured fourth monthly extension with $55,823.80 trust deposit
- Company maintains ability to extend deadline up to October 2025
- Management remains committed to securing Nasdaq listing for post-merger entity
- Delisting from Nasdaq, moving to less prestigious OTC Markets
- Required additional time extension for business combination completion
- Monthly extension payments reducing cash reserves ($0.05 per Class A share)
- Business combination closing date remains uncertain despite approval
Insights
Aimfinity's Nasdaq delisting and fourth extension signal deal complications, creating uncertainty despite commitment to complete the Docter acquisition.
Aimfinity Investment Corp. I's transition from Nasdaq to OTC Markets represents a significant development that typically impacts trading dynamics. Securities trading on OTC markets generally experience reduced liquidity, wider bid-ask spreads, and lower visibility compared to major exchanges. This transition, while described as "anticipated" in the release, creates a material change in how shares will trade beginning May 5.
The company's need for a fourth monthly extension (of nine possible) to complete its business combination with Docter Inc. is particularly notable. Each extension requires additional capital contributions from the sponsor - in this case
While the delisting creates challenges, management explicitly states they "remain committed" to both closing the transaction and eventually securing Nasdaq listing for the post-combined entity. This suggests the OTC transition may be temporary if they can successfully complete the business combination and meet Nasdaq listing requirements afterward.
The extension mechanism, allowing monthly extensions until October 2025, provides a structured timeline for deal completion, but each passing month without closure introduces additional uncertainty. This fourth extension pushes the completion deadline to May 28, 2025, giving management another month to finalize the transaction with Docter, a Taiwanese health technology company.
Wilmington, DE, April 30, 2025 (GLOBE NEWSWIRE) -- Aimfinity Investment Corp. I (the “AIMA”) (Nasdaq: AIMAU), a special purpose acquisition company, today announced that, as anticipated, AIMA received a notice from The Nasdaq Stock Market LLC (“Nasdaq” or the “Exchange”), stating that in accordance with Nasdaq rules, its securities will be delisted from the Exchange. At the open of trading on Monday, May 5, 2025, AIMA’s securities will be suspended on Nasdaq and are expected to begin trading on the OTC Markets under the tickers “AIMAU,” “AIMBU,” and “AIMAW”, for its units, new units and warrants, respectively.
AIMA’s previously announced business combination (the "Business Combination") with Docter Inc. (“Docter”), a Taiwanese health technology company, which received shareholder approval on March 27, 2025, will not be materially affected by the venue change, as AIMA and Docter remain committed to working closely to secure Nasdaq listing approval for the post-combined entity and to close the Business Combination as soon as practicable.
In addition, in order to extend the date by which AIMA must complete the Business Combination from April 28, 2025 to May 28, 2025, on April 28, 2025, I-Fa Chang, manager of the sponsor of AIMA, deposited into AIMA’s trust account (the “Trust Account”) an aggregate of
Pursuant to AIMA’s fourth amended and restated memorandum and articles of association (“Current Charter”), effective January 9, 2025, AIMA may extend the date by which AIMA must complete the Business Combination on a monthly basis from January 28, 2025 until October 28, 2025 or such earlier date as may be determined by its board of directors by depositing the Monthly Extension Payment for each month into the Trust Account. This is the fourth of nine monthly extensions available under the Current Charter of AIMA.
About Aimfinity Investment Corp. I
Aimfinity Investment Corp. I is a special purpose acquisition company (SPAC) focused on merging with high-growth potential businesses and facilitating their entry into the capital markets.
About Docter Inc.
Docter Inc. is a leading health technology company dedicated to developing innovative health monitoring solutions that enhance the accessibility and efficiency of global healthcare services.
Additional Information and Where to Find It
As previously disclosed, on October 13, 2023, AIMA entered into that certain Agreement and Plan of Merger (as may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and between AIMA, Docter, Aimfinity Investment Merger Sub I, a Cayman Islands exempted company and wholly-owned subsidiary of AIMA (“Purchaser”), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of Purchaser (“Merger Sub”), pursuant to which AIMA is proposing to enter into a business combination with Docter involving an reincorporation merger and an acquisition merger. This press release does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. AIMA’s shareholders and other interested persons are advised to read, when available, the proxy statement/prospectus and the amendments thereto and other documents filed in connection with the proposed business combination, as these materials will contain important information about AIMA, Purchaser or Docter, and the proposed business combination. The proxy statement/prospectus and other relevant materials for the proposed business combination have been mailed to shareholders of AIMA as of the record date of February 25, 2025, established for voting on the proposed business combination. Such shareholders will also be able to obtain copies of the proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to AIMA’s principal office at 221 W 9th St, PMB 235 Wilmington, Delaware 19801.
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended. Statements that are not historical facts, including statements about the proposed transactions described herein, and the parties’ perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the proposed transaction, including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the proposed transactions. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.
Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the proposed business combination, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate the businesses; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iv) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of AIMA or Docter; (v) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (vi) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of AIMA’s securities; (vii) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Docter to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (viii) risks relating to the medical device industry, including but not limited to governmental regulatory and enforcement changes, market competitions, competitive product and pricing activity; and (ix) risks relating to the combined company’s ability to enhance its products and services, execute its business strategy, expand its customer base and maintain stable relationship with its business partners.
A further list and description of risks and uncertainties can be found in the prospectus filed with the Securities and Exchange Commission (the “SEC”) on April 26, 2022 relating to AIMA’s initial public offering (File No. 333-263874), the annual report of AIMA on Form 10-K for the fiscal year ended on December 31, 2024, filed with the SEC on April 15, 2025, and in the final prospectus/proxy statement filed with the SEC on March 6, 2025 relating to the proposed transactions (File No. 333-284658) (the “Final Prospectus”), and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and AIMA, Docter, and their subsidiaries or affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
Additional Information and Where to Find It
In connection with the proposed transactions described herein, Purchaser filed the Final Prospectus with the SEC on March 6, 2025. The proxy statement and a proxy card has been mailed to AIMA’s shareholders of record as of February 25, 2025. Shareholders of AIMA will also be able to obtain a copy of the Final Prospectus without charge from AIMA. The Final Prospectus may also be obtained without charge at the SEC’s website at www.sec.gov. INVESTORS AND SECURITY HOLDERS OF AIMA ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTIONS THAT AIMA WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AIMA, DOCTER AND THE PROPOSED TRANSACTIONS.
Participants in the Solicitation
AIMA, Docter, and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of AIMA’s shareholders in connection with the proposed transactions described herein. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of AIMA’s shareholders in connection with the proposed business combination is set forth in the Final Prospectus.
No Offer or Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of any potential transaction and does not constitute an offer to sell or a solicitation of an offer to buy any securities of AIMA, Purchaser or Docter, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.
Contact Information:
Aimfinity Investment Corp. I
I-Fa Chang
Chief Executive Officer
221 W 9th St, PMB 235
Wilmington, Delaware 19801
ceo@aimfinityspac.com
FAQ
Why is AIMAU moving from Nasdaq to OTC Markets on May 5, 2025?
Will AIMAU's business combination with Docter be affected by the Nasdaq delisting?
How long is AIMAU's latest extension for completing the Docter merger?
How many more monthly extensions can AIMAU request for the Docter merger?
What happens to AIMAU shareholders after the OTC Markets transition?
